Management of anemia and iron deficiency in a cancer center in France

Supportive Care in Cancer

Volumn 24, Issue 3, 2016, Pages 1091-1096

  Laï Tiong, Florence ^a   Brami, Cloé ^a   Dubroeucq, Olivier ^a   Scotté, Florian ^b   Curé, Hervé ^a   Jovenin, Nicolas ^a  

^a Jean Godinot Unicancer Institute   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anemia; Cancer induced anemia; Chemotherapy induced anemia; Intravenous iron; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; FEMALE; FEMALE GENITAL TRACT CANCER; FERRITIN BLOOD LEVEL; FRANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BALANCE; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; COMPLICATION; DEFICIENCY; DISEASE MANAGEMENT; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; FEMALE; FRANCE; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 84955751902     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2877-4     Document Type: Article

References (42)

1. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum Ann Oncol 11(8):971–975
2. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95(1):155–163
3. Sabbatini P (2000) Contribution of anemia to fatigue in the cancer patient. Oncology (Williston Park) 14(11a):69–71
4. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91(19):1616–1634
5. Demetri GD (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84(Suppl):131–137
6. Gordon MS (2002) Managing anemia in the cancer patient: old problems, future solutions. Oncologist 7(4):331–341
7. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, et al. (2006) Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 70(1):34–48
8. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23(8):1954–1962
9. Bron D, Meuleman N, Mascaux C (2001) Biological basis of anemia. Semin Oncol 28(2 Suppl 8):1–6
10. Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24(7):1886–1892
11. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12):2214–2221
12. Harper P, Littlewood T (2005) Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69(Suppl):22–27
13. Sabbatini P (2000) The relationship between anemia and quality of life in cancer patients. Oncologist 5(Suppl):219–223
14. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15):2293–2306
15. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl):333–336
16. Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244–v27.
17. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270
18. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13–19
19. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P, Anemia Study Group (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37(13):1617–1623
20. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17(9):2840–2846
21. Spielmann M, Luporsi E, Ray-Coquard I, de Botton S, Azria D, Lasocki S, et al. (2012) Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009–2010: the AnemOnHe study. Eur J Cancer 48(1):101–107
22. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, et al. (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22(8):2197–2206
23. Schneider M (2005) Fréquence de l’anémie chez les patients français atteints de tumeurs solides ou d’hémopathies malignes: résultats de l’«European Cancer Anaemia Survey (ECAS)». Oncologie 7(5):397–402
24. Guardiola E, Morschhauser F, Zambrowski J-J, Antoine E-C (2007) Prise en charge de l’anémie chez les patients présentant une pathologie maligne: résultats de l’étude. F-ACT (Fr Anaemia Cancer Treat) Bull Cancer 94(10):907–914
25. Link H, Schmitz S (2013) Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 36(5):266–272
26. Association Francophone pour les Soins Oncologique de Support (AFSOS) (2012) Anémie et cancer. Available from: http://ftp.comm-sante.com/SB/anemieetcancer.pdf
27. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241–1251
28. Cook JD (2005) Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 18(2):319–332
29. Venables WN, Ripley BD (2002) Modern applied statistics with S. Springer, Fourth Edition
30. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
31. Lichtin AE (2011) Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC. NCCN Cancer Treat Res 157239-48
32. Gafter-Gvili A, Steensma DP, Auerbach M (2014) Should the ASCO/ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Cancer Netw 12(5):657–664
33. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116(20):4045–4059
34. Ludwig H, Fritz E (1998) Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 25(3 Suppl 7):35–38
35. Busti F, Campostrini N, Martinelli N, Girelli D (2014) Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol 583
36. Eisenstaedt R, Penninx BW, Woodman RC (2006) Anemia in the elderly: current understanding and emerging concepts. Blood Rev 20(4):213–226
37. Chaves PH, Ashar B, Guralnik JM, Fried LP (2002) Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 50(7):1257–1264
38. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22(7):1301–1307
39. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26(10):1611–1618
40. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21(4):627–632
41. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12(2):231–242
42. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26(10):1619–1625